A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain.

Trial Profile

A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2015

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2012 Planned end date changed from 1 Jun 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Actual initiation date changed from 1 Jun 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top